Sodium glucose co-transport 2 (SGLT2) inhibitors are relatively new drugs included in the management of type 2 diabetes over the recent decade. These agents lower blood glucose by inhibiting glucose reabsorption in the proximal renal tubules. SGLT2 inhibitors also have some other effects such as weight reduction. Does weight-reducing effect of SGLT2 inhibitors among patients with type 2 diabetes constitutes a therapeutic significance.
There is an emerging weight-reducing role of SGLT-2 inhibitors. This make these drugs potential new therapeutic agents for the treatment of obesity particularly
when combined with other drugs with weight-lowering profile. The administration of SGLT2 inhibitors with Glucagon like peptide-1 receptor agonist (GLP1-RA) causes a noticeable reduction in body weight. The weight loss is mainly due to a reduction in subcutaneous and visceral adipose tissue, rather than lean tissue.
The following link is useful in this regard:
https://link.springer.com/article/10.1007/s40265-019-1057-0#:~:text=Co%2Dadministration%20of%20SGLT2%20inhibitors%20with%20GLP1%2DRA%20reduces%20body,diabetes%20%5B21%2C%2030%5D.
Also, the following links are useful in this aspect:
Article Effects of SGLT2 inhibitors on weight loss in patients with ...
Article Weight loss associated with sodium-glucose cotransporter-2 i...
SGLT2 inhibitors have been shown to be successful in improving glycaemic control and lowering body weight. A great deal of evidence has indicated that SGLT-2 inhibitors have strong effects on body weight in patients with diabetes mellitus and can be used as potential agents for obesity management.
The ability to reduce body weight is consistently observed in individuals taking SGLT2 inhibitors, but this weight loss is moderate due to counter-regulatory mechanisms striving to maintain body weight. This has prompted exploration of SGLT2 inhibitors in combination with other agents acting via decreased food intake, e.g., glucagon-like peptide 1 receptor agonists (GLP1-RAs). The bodyweight effects are promising, and together with the signs of prevention of cardiovascular and renal events, such combinations including SGLT2 inhibitors are appealing. The weight loss is clinically important, as most individuals with type 2 diabetes are overweight or obese, but also because there is an unmet need for safe, effective, and durable weight loss interventions in obese individuals without diabetes.
https://pubmed.ncbi.nlm.nih.gov/30701480/
I think this link is helpful
https://onlinelibrary.wiley.com/doi/full/10.1111/obr.12841
This article also helpful.
Dear Dr Ruqaya Adnan Salih. Really you have presented wonderful and valuable replies with regard to weight-reducing effect of SGLT2 inhibitors with them I fully agree. Many thanks for your valuable contribution and also for sharing valuable links that greatly enriched the discussion. My sincere gratitude.
The weight-reducing effect of SGLT-2 is an important factor in reducing the risk of chronic complications of diabetes. We have data that show a clear correlation between BMI and the presence of chronic complications and cardiovascular risk. This is probably related to endothelial dysfunction and chronic inflammation which is present in people with diabetes and is further aggravated by obesity. The reduction in the risk of complications provided by SGLT-2 is also an argument for their usefulness in type 1 diabetes. In conclusion, weight loss on SGLT-2 will certainly not reverse the current chronic complications, but will definitely reduce their further progression.
Dear Monika Klimek-Tulwin The weight-reducing effect of SGLT2 inhibitors and the subsequent reduction in the risk of complications of diabetes is an indication for the promising usefulness of these drugs in the management of patients with type 2 diabetes. Many thanks Dr. indeed for your valuable contribution. Kind regards. .
Dear Dr Salman Kadhum Ajlan . Yes . See the following useful RG link: Article SGLT2 Inhibitors and the Clinical Implications of Associated...
Kindly see also the following good RG link: Article Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Also check please the following good RG link: Article Effect of sodium–glucose co-transporter-2 inhibitors on the ...
The following RG link is also very useful: Article Comparisons of weight changes between SGLT2 inhibitors treat...
Also check please the following good RG link: Article SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
Dear Dr Aref Wazwaz. Really many thanks for your valuable contribution and sharing very useful links that greatly enriched the discussion. My sincere gratitude.
You are most welcome dear
Dr Salman Kadhum Ajlan
Wish you the best always
Dear Dr Aref Wazwaz. I'm so grateful for your valuable participation in the discussion. Kind regards and best wishes.
Thank you Dr. Salman Ajlan for this question and valuable discussion & informative link shared by this discussion.
Dear Dr. Ruqaya Adnan Salih I'm really grateful for your valuable contribution and your kind words. I wish you all the best. Kind regards.
SGLT-2 inhibitors of dual SGLT-1 &SGLT-2 combination, although, beneficial in cardio-renal protection, blood pressure, and weight reduction. However, they are not licensed for weight management. GLP-1 like agonists Semaglutide and liraglutide are licensed for high body mass index reduction.
Dear Dr. Hyder Mirghani. Really many thanks for your kind contribution and valuable reply with regard to SGLT2 inhibitors. My sincere gratitude.
Glycuria, which causes a 300-calorie deficit, is the mechanism through which SGLT2 inhibitors cause weight reduction. Inhibition of sodium and glucose reabsorption can also cause an osmotic diuresis, which can help you lose weight by reducing water retention. SGLT2 inhibitors, unlike other antidiabetics, provide an insulin-independent mechanism for lowering blood sugar and facilitating weight loss.
https://www.uspharmacist.com/article/management-of-obesity-in-patients-with-diabetes
Insulin therapy, which is used to treat both type 1 and type 2 diabetes, can cause weight gain. The addition of SGLT2 inhibitors to insulin may improve glycemic control, reduce the quantity of insulin required, and reduce insulin-related weight gain in people with type 2 diabetes.
https://www.diabetesincontrol.com/what-you-need-to-know-about-sglt2i-use-in-obesity/
Also, kindly check:
Article SGLT2 Inhibitors and the Clinical Implications of Associated...
Dear Dr. Manal Hadi Kanaan Really many thanks for your kind contribution and valuable answers that greatly enriched the discussion. Also, sharing valuable links and article is gratefully acknowledged. My sincere gratitude.